ATE204751T1 - Mittel zur arzneistoffabgabe im colon - Google Patents

Mittel zur arzneistoffabgabe im colon

Info

Publication number
ATE204751T1
ATE204751T1 AT95922632T AT95922632T ATE204751T1 AT E204751 T1 ATE204751 T1 AT E204751T1 AT 95922632 T AT95922632 T AT 95922632T AT 95922632 T AT95922632 T AT 95922632T AT E204751 T1 ATE204751 T1 AT E204751T1
Authority
AT
Austria
Prior art keywords
colon
drug
medicinal
delivery
agents
Prior art date
Application number
AT95922632T
Other languages
English (en)
Inventor
Peter Watts
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Application granted granted Critical
Publication of ATE204751T1 publication Critical patent/ATE204751T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95922632T 1994-06-21 1995-06-21 Mittel zur arzneistoffabgabe im colon ATE204751T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412394A GB9412394D0 (en) 1994-06-21 1994-06-21 Colonic drug delivery composition
PCT/GB1995/001458 WO1995035100A1 (en) 1994-06-21 1995-06-21 Colonic drug delivery composition

Publications (1)

Publication Number Publication Date
ATE204751T1 true ATE204751T1 (de) 2001-09-15

Family

ID=10757052

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95922632T ATE204751T1 (de) 1994-06-21 1995-06-21 Mittel zur arzneistoffabgabe im colon

Country Status (14)

Country Link
US (2) US6228396B1 (de)
EP (1) EP0810857B1 (de)
JP (1) JP2986217B2 (de)
AT (1) ATE204751T1 (de)
AU (1) AU688060B2 (de)
CA (1) CA2193481C (de)
DE (1) DE69522475T2 (de)
DK (1) DK0810857T3 (de)
ES (1) ES2162922T3 (de)
FI (1) FI118626B (de)
GB (1) GB9412394D0 (de)
NO (1) NO315686B1 (de)
PT (1) PT810857E (de)
WO (1) WO1995035100A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
CA2271560C (en) * 1996-11-15 2003-09-23 Mayo Foundation For Medical Education And Research Pharmaceutical dosage form for colonic delivery
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
GB9800912D0 (en) * 1998-01-17 1998-03-11 Danbiosyst Uk New composition
CA2320087C (en) * 1998-02-09 2006-12-19 Joel Bolonick Treatment of chronic inflammatory disorders of the gastrointestinal tract
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
MXPA01003197A (es) 1998-09-28 2004-04-21 Warner Lambert Co Suministro enterico y colonico utilizando capsulas de chpm.
DE19923817A1 (de) * 1999-05-18 2000-11-23 Roland Bodmeier Kapsel mit kontrollierter Wirkstofffreisetzung
AU5108200A (en) 1999-06-09 2000-12-28 Mochida Pharmaceutical Co., Ltd. System for release in lower digestive tract
US6340473B1 (en) * 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
IT1318625B1 (it) * 2000-07-14 2003-08-27 Roberto Valducci Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente.
AU2002232955A1 (en) 2000-11-20 2002-05-27 Dow Global Technologies Inc. In vivo use of water absorbent polymers
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US7012068B2 (en) 2001-03-27 2006-03-14 Pro-Pharmaceuticals, Inc. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
WO2004098647A2 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins’ underexpression as markers of tumor metastasis
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
EP1718146A2 (de) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von akne und candida
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US20080286251A1 (en) * 2004-08-02 2008-11-20 Propharmaceuticals, Inc. Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
GB0421121D0 (en) * 2004-09-22 2004-10-27 Natrocell Technologies Ltd Composite rodenticide
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
US20080057086A1 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
RU2009116271A (ru) * 2006-09-29 2010-11-10 Конинклейке Филипс Электроникс, Н.В. (Nl) Миниатюрные пороговые датчики
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090269405A1 (en) * 2008-04-08 2009-10-29 Appian Labs, Llc Enzyme mediated delivery system
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
PL3692983T3 (pl) * 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2015161139A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US20120276056A1 (en) * 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
KR20190120430A (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
CA3008794C (en) * 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
US20140066837A1 (en) 2012-07-26 2014-03-06 Ronald L. Moy Skin care compositions and methods
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
KR20150144743A (ko) * 2013-04-05 2015-12-28 폴리켐 에스.에이. 염증성 장 질환을 치료하기 위한 피도티모드의 사용
CA2901284A1 (en) 2013-04-05 2014-10-09 Polichem Sa Use of pidotimod to treat irritable bowel syndrome
EP3089737B1 (de) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Orale rapamycinnanopartikelzubereitungen und verwendung
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
DK3107568T3 (da) * 2014-02-20 2024-06-03 Vaxart Inc Formuleringer til indgivelse til tyndtarmen
AU2015305449B2 (en) 2014-08-22 2021-05-06 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
EA201792512A1 (ru) 2015-06-12 2018-06-29 Вэксарт, Инк. Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
PE20181295A1 (es) 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
CN106380636B (zh) * 2016-08-30 2019-05-14 华南理工大学 一种壳聚糖接枝的抗消化淀粉载体材料及其制备方法和应用
CN108201531A (zh) * 2016-12-19 2018-06-26 湖南尔康湘药制药有限公司 高溶解性磺苄西林钠结肠靶向淀粉胶囊及其制备方法
US11596607B2 (en) 2017-04-18 2023-03-07 Actorious Innovations And Research Pvt. Ltd. Polymer based formulation for release of drugs and bioactives at specific GIT sites
JP2021528483A (ja) * 2018-05-03 2021-10-21 エムダブリュ エンキャップ リミテッド 下部胃腸管への医薬の送達のための剤形
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
WO2021188564A1 (en) 2020-03-16 2021-09-23 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US20240197639A1 (en) 2021-04-20 2024-06-20 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Capsule for specific drug delivery and preparation method therefor
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4738724A (en) * 1983-11-04 1988-04-19 Warner-Lambert Company Method for forming pharmaceutical capsules from starch compositions
US4673438A (en) * 1984-02-13 1987-06-16 Warner-Lambert Company Polymer composition for injection molding
US4663308A (en) 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
US4627851A (en) 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
US4945080A (en) * 1987-05-26 1990-07-31 Eli Lilly And Company Dirithromycin metabolite
EP0313845A1 (de) * 1987-09-29 1989-05-03 Warner-Lambert Company Stabilisierung von enterischen beschichteten Dosierungsformen
ES2041336T3 (es) * 1987-11-20 1993-11-16 Greither, Peter Capsula y procedimiento para su fabricacion.
DE8715583U1 (de) * 1987-11-24 1988-01-28 Greither, Peter, Kirchberg Kapsel
DE3812799A1 (de) 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
US5342624A (en) * 1989-02-16 1994-08-30 British Technology Group Ltd. Dispensing device
EP0425699B1 (de) 1989-05-11 1994-08-17 Chugai Seiyaku Kabushiki Kaisha Mundzubereitung zur verabreichung an bestimmter stelle des darmes
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
BE1003677A3 (nl) * 1990-01-29 1992-05-19 Schacht Etienne Werkwijze voor het bereiden van azobevattende polymeren en het gebruik ervan als geneesmiddelafgiftesystemen.
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
HU227530B1 (en) * 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
DE4236025A1 (de) 1992-10-24 1994-04-28 Merck Patent Gmbh Orale Arzneiformen
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
JP3725539B2 (ja) 1993-02-26 2005-12-14 大正製薬株式会社 ビサコジル剤形
DE69425453T2 (de) 1993-04-23 2001-04-12 Novartis Ag, Basel Wirkstoffabgabevorrichtung mit gesteuerter Freigabe
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
JP3725542B2 (ja) 1993-10-19 2005-12-14 大正製薬株式会社 ピコサルフェート剤形
US5514663A (en) 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
JPH09510182A (ja) * 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same

Also Published As

Publication number Publication date
ES2162922T3 (es) 2002-01-16
EP0810857B1 (de) 2001-08-29
NO315686B1 (no) 2003-10-13
JPH09510478A (ja) 1997-10-21
CA2193481C (en) 2001-03-20
FI965154L (fi) 1997-02-20
NO965436L (no) 1996-12-18
AU2746095A (en) 1996-01-15
FI965154A0 (fi) 1996-12-20
GB9412394D0 (en) 1994-08-10
NO965436D0 (no) 1996-12-18
DK0810857T3 (da) 2001-10-08
EP0810857A1 (de) 1997-12-10
DE69522475D1 (de) 2001-10-04
CA2193481A1 (en) 1995-12-28
FI118626B (fi) 2008-01-31
DE69522475T2 (de) 2002-05-08
US6228396B1 (en) 2001-05-08
WO1995035100A1 (en) 1995-12-28
AU688060B2 (en) 1998-03-05
US20010026807A1 (en) 2001-10-04
JP2986217B2 (ja) 1999-12-06
PT810857E (pt) 2001-12-28

Similar Documents

Publication Publication Date Title
ATE204751T1 (de) Mittel zur arzneistoffabgabe im colon
GR3033301T3 (en) Medicament form for the delivery of active substances to wounds
YU49354B (sh) Oralne tečne formulacije alendronata
AU4879396A (en) Use of inorganic aerogels in pharmacy
MA26853A1 (fr) Compositions pharmaceutiques engendrant des concentrations accrues de medicaments
NO20064395L (no) Anvendelse av buprenorfin i fremstilling av et medikament
PT1028707E (pt) Formulacoes oftalmicas de libertacao controlada contendo medicamentos soluveis em agua
PT1006935E (pt) Sistema de entrega controlada liquido de alta viscosidade
CA2141704A1 (fr) Solutions aqueuses concentrees d'argatroban
NO20005394D0 (no) Legemiddelavleveringssammensetninger bestÕende av klebende mikrosfærer
ME00578A (en) Use of gastrointestinal lipase inhibitors
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
TR199802351T2 (xx) Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi.
GB9814215D0 (en) Anti-inflammatory pharmaceutical formulations
UA39884C2 (uk) Таблетка на основі клодронової кислоти, спосіб її одержання та спосіб лікування остеопорозу
AU668767B2 (en) Oral medicament form
FR2735132B1 (fr) Medicament polypeptidique modifie, composition et dispositif d'administration par electrotransport le contenant
TR199903211T2 (xx) Azasteroitler içeren çözeltiler.
MY117808A (en) Cancer cell nuclease activator
ES2126265T3 (es) Tableta de accion retardada con un cierto contenido de diclorofenaco de sodio.
ATE292954T1 (de) Schutz zur verminderung von zahnbelag
DE59607949D1 (de) Feste arzneimittelform mit polymerem material verteiltem wirkstoff
PL315619A1 (en) Oral form of a drug containing acid active substances and method of obtaining same
GB2303550A (en) Colonic drug delivery composition
GB9827034D0 (en) Delivery formulation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEFA Change of the company name